PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

Nature Reviews Clinical Oncology

Volumn 14, Issue 4, 2017, Pages 203-220

  Goodman, Aaron ^a   Patel, Sandip P ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BRENTUXIMAB VEDOTIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DARATUMUMAB; DURVALUMAB; IPILIMUMAB; LENALIDOMIDE; LIRILUMAB; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; POMALIDOMIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TICILIMUMAB; UBLITUXIMAB; URELUMAB; UTOMILUMAB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DIFFUSE LARGE B CELL LYMPHOMA; DISEASE ASSOCIATION; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; MEDIASTINUM TUMOR; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T CELL LEUKEMIA; ANTAGONISTS AND INHIBITORS; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MEDIASTINAL NEOPLASMS; METABOLISM; PROCEDURES; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HODGKIN DISEASE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MEDIASTINAL NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR ESCAPE;

EID: 84994120928     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.168     Document Type: Review

References (166)

1. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2105 (1999).
2. Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6, S11-14 (2000).
3. Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6, S55-S57 (2000).
4. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
5. Walunas, T. L., Bakker, C. Y. & Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541-2550 (1996).
6. Freeman, G. J. et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
7. Greaves, P. & Gribben, J. G. The role of B7 family molecules in hematologic malignancy. Blood 121, 734-744 (2013).
8. Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227-242 (2013).
9. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
10. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
11. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
12. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
13. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
14. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
15. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
16. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
17. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
18. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
19. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
20. Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847-856 (2015).
21. Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690-2697 (2016).
22. Shi, M. et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am. J. Surg. Pathol. 38, 1715-1723 (2014).
23. Chapuy, B. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127, 869-881 (2016).
24. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
25. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
26. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
27. Carreras, J. et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 27, 1470-1476 (2009).
28. Richendollar, B. G., Pohlman, B., Elson, P. & Hsi, E. D. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum. Pathol. 42, 552-557 (2011).
29. Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23, 5027-5033 (2005).
30. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
31. Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107, 265-276 (2006).
32. Johnson, P. & McKenzie, H. How I treat advanced classical Hodgkin lymphoma. Blood 125, 1717-1723 (2015).
33. Ng, A. K. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br. J. Haematol. 154, 23-31 (2011).
34. Lavoie, J. C. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106, 1473-1478 (2005).
35. Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012).
36. Chen, R. et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128, 1562-1566 (2016).
37. Chen, R. et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119, 6379-6381 (2012).
38. Marshall, N. A. et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103, 1755-1762 (2004).
39. Chemnitz, J. M. et al. RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood 110, 3226-3233 (2007).
40. Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611-1618 (2012).
41. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
42. Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19, 3462-3473 (2013).
43. Yamamoto, R. et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111, 3220-3224 (2008).
44. Yamamoto, R. et al. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 100, 2093-2100 (2009).
45. Hao, Y. et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin. Cancer Res. 20, 2674-2683 (2014).
46. Kozako, T. et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23, 375-382 (2009).
47. Advani, R. H. et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J. Clin. Oncol. 32, 912-918 (2014).
48. Eichenauer, D. A. et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J. Clin. Oncol. 33, 2857-2862 (2015).
49. Dorfman, D. M., Brown, J. A., Shahsafaei, A. & Freeman, G. J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 30, 802-810 (2006).
50. Armand, P. et al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. J. Clin. Oncol. http://dx.doi.org/ 10.1200/JCO.2016.67.3467 (2016).
51. Chen, R. et al. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J. Clin. Oncol. 34 (Suppl.), abstr. 7555 (2016).
52. Younes, A. et al. Checkmate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) - a phase 2 study. J. Clin Oncol. 34 (Suppl.), abstr. 7535 (2016).
53. US Food and Drug Administration. Nivolumab (Opdivo) for Hodgkin lymphoma. FDA http://www.fda. gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm501412.htm (2016).
54. Tsimberidou, A.-M., Braiteh, F., Stewart, D. J. & Kurzrock, R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J. Clin. Oncol. 27, 6243-6250 (2009).
55. Armand, P. et al. A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D [abstract]. J. Clin. Oncol. 34 (Suppl.), TPS7573 (2016).
56. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02758717 (2016).
57. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02581631 (2016).
58. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01896999 (2016).
59. Dunleavy, K. & Wilson, W. H. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 125, 33-39 (2015).
60. Dunleavy, K. et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 368, 1408-1416 (2013).
61. Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879 (2003).
62. Twa, D. D. W. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123, 2062-2065 (2014).
63. Chong, L. C. et al. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. Blood 128, 1206-1213 (2016).
64. Twa, D. D. W. & Steidl, C. Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leuk. Lymphoma 56, 2239-2250 (2015).
65. Yuan, J. et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling: Am. J. Surg. Pathol. 39, 1322-1330 (2015).
66. Steidl, C. & Gascoyne, R. D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118, 2659-2669 (2011).
67. Weniger, M. A. et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes. Chromosomes Cancer 46, 406-415 (2007).
68. Gowrishankar, K. et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS ONE http:// dx.doi.org/10.1371/journal.pone.0123410 (2015).
69. Lesokhin, A. M. et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J. Clin. Oncol. 34, 2698-2704 (2016).
70. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02576990 (2016).
71. Armitage, J. O. How I treat patients with diffuse large B-cell lymphoma. Blood 110, 29-36 (2007).
72. Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22-32 (2015).
73. Ziepert, M. et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 2373-2380 (2010).
74. Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184-4190 (2010).
75. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
76. Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68-74 (2002).
77. Andorsky, D. J. et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 17, 4232-4244 (2011).
78. Menter, T., Bodmer-Haecki, A., Dirnhofer, S. & Tzankov, A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum. Pathol. 54, 17-24 (2016).
79. Nicolae, A. et al. EBV-positive large B cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126, 863-872 (2015).
80. Kiyasu, J. et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126, 2193-2201 (2015).
81. Baumjohann, D., Baumjohann, D. & Ansel, K. M. Identification of T follicular helper (Tfh) cells by flow cytometry. Protoc. Exch. http://dx.doi.org/10.1038/ protex.2013.060 (2013).
82. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011).
83. Good-Jacobson, K. L. et al. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11, 535-542 (2010).
84. Kim, J. R. et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 8, e82870 (2013).
85. Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (2007).
86. Ahearne, M. J. et al. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch. 465, 351-358 (2014).
87. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014).
88. Rossille, D. et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 28, 2367-2375 (2014).
89. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
90. Carroll, J. Anti-PD-1- Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study. FierceBiotech http://www.fiercebiotech.com/r-d/anti-pd-1-well-no-says-medivation-as-a-partial-hold-forces-a-halt-to-pivotal-cancer-study (2016).
91. Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199-4206 (2013).
92. Silverberg, M. J. & Abrams, D. I. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr. Opin. Intern. Med. 6, 642-647 (2007).
93. Dunleavy, K. & Wilson, W. H. How I treat HIV-associated lymphoma. Blood 119, 3245-3255 (2012).
94. Bower, M. How I treat HIV-associated multicentric Castleman disease. Blood 116, 4415-4421 (2010).
95. Little, R. F. & Dunleavy, K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am. Soc. Hematol. Educ. Program 2013, 382-388 (2013).
96. Olszewski, A. J., Fallah, J. & Castillo, J. J. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer 122, 2689-2697 (2016).
97. Sparano, J. A. et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J. Natl Cancer Inst. 89, 301-307 (1997).
98. Chao, C. et al. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann. Oncol. 25, 1821-1829 (2014).
99. Carbone, A. et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat. Rev. Clin. Oncol. 11, 223-238 (2014).
100. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
101. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
102. Shankar, P. et al. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood 96, 3094-3101 (2000).
103. Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
104. Velu, V., Shetty, R. D., Larsson, M. & Shankar, E. M. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 12, 14 (2015).
105. Banga, R. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754-761 (2016).
106. Cubas, R. A. et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19, 494-499 (2013).
107. Pillai, S. Love the one you're with: the HIV, B cell and TFH cell triangle. Nat. Med. 19, 401-402 (2013).
108. Kahl, B. S. & Yang, D. T. Follicular lymphoma: evolving therapeutic strategies. Blood 127, 2055-2063 (2016).
109. Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80, 879-886 (1992).
110. Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42-51 (2011).
111. Witzig, T. E. et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 5404-5409 (2009).
112. Flinn, I. W. et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123, 3406-3413 (2014).
113. van Besien, K. et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102, 3521-3529 (2003).
114. de Jong, D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J. Clin. Oncol. 23, 6358-6363 (2005).
115. Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159-2169 (2004).
116. Smeltzer, J. P. et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin. Cancer Res. 20, 2862-2872 (2014).
117. Myklebust, J. H. et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121, 1367-1376 (2013).
118. Nakanishi, J. et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56, 1173-1182 (2006).
119. Wu, C. et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108, 19-24 (2006).
120. Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69-77 (2014).
121. Davis, T. A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135-3143 (2000).
122. Frassanito, M. A., Cusmai, A. & Dammacco, F. Deregulated cytokine network and defective Th1-immune response in multiple myeloma. Clin. Exp. Immunol. 125, 190-197 (2001).
123. Hideshima, T., Bergsagel, P. L., Kuehl, W. M. & Anderson, K. C. Advances in biology of multiple myeloma: clinical applications. Blood 104, 607-618 (2004).
124. Tamura, H. et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27, 464-472 (2013).
125. Liu, J. et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110, 296-304 (2007).
126. Benson, D. M. et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010).
127. Hallett, W. H. D., Jing, W., Drobyski, W. R. & Johnson, B. D. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transplant. 17, 1133-1145 (2011).
128. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
129. Kearl, T. J., Jing, W., Gershan, J. A. & Johnson, B. D. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J. Immunol. 190, 5620-5628 (2013).
130. Jungbluth, A. A. et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106, 167-174 (2005).
131. Goodyear, O. et al. CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106, 4217-4224 (2005).
132. Alyea, E. et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934-939 (2001).
133. Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207-1219 (2015).
134. Krejcik, J. et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384-394 (2016).
135. Luptakova, K. et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol. Immunother. 62, 39-49 (2013).
136. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02431208 (2016).
137. Wilcox, R. A. et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114, 2149-2158 (2009).
138. Marzec, M. et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl Acad. Sci. USA 105, 20852-20857 (2008).
139. Xerri, L. et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum. Pathol. 39, 1050-1058 (2008).
140. Han, L. et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol. Lett. 8, 1461-1469 (2014).
141. Kantekure, K. et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am. J. Dermatopathol. 34, 126-128 (2012).
142. Munir, S. et al. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27, 2251-2253 (2013).
143. Miyoshi, H. et al. PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 128, 1374-1381 (2016).
144. Maloney, D. G. Graft-versus-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk. Lymphoma 44, S99-S105 (2003).
145. Fenske, T. S. et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. Biol. Blood Marrow Transplant. 22, 1543-1551 (2016).
146. Pingali, S. & Champlin, R. Pushing the envelope - nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 50, 1157-1167 (2015).
147. Chang, X., Zang, X. & Xia, C.-Q. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant. 51, 324-332 (2016).
148. Deng, R. et al. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J. Immunol. 194, 560-574 (2015).
149. Blazar, B. R. et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J. Immunol. 171, 1272-1277 (2003).
150. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Sharpe, A. H. & Vallera, D. A. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162, 6368-6377 (1999).
151. Okiyama, N. & Katz, S. I. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J. Autoimmun. 53, 1-9 (2014).
152. Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143-153 (2016).
153. Straub, M. et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 7, 12024-12034 (2016).
154. Barrett, M. T. et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6, 26483-26493 (2015).
155. Ikeda, S. et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. Genomic Med. 1, 16037 (2016).
156. Nanda, R., Chow, L. & Dees, E. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 75 (Suppl.), abstr. S1-09 (2014).
157. Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
158. Killock, D. Immunotherapy: study deciphers enigmatic mechanism of PD-L1 overexpression. Nat. Rev. Clin. Oncol. 13, 395-395 (2016).
159. Bally, A. P., Austin, J. W. & Boss, J. M. Genetic and epigenetic regulation of PD-1 expression. J. Immunol. 196, 2431-2437 (2016).
160. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
161. Nakamura, N. et al. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. Int. J. Hematol. 102, 327-334 (2015).
162. Ju, W. et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or navitoclax in a murine model of human Hodgkin's lymphoma. Proc. Natl Acad. Sci. USA 113, 1624-1629 (2016).
163. Sagiv-Barfi, I. et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl Acad. Sci. USA 112, E966-E972 (2015).
164. Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539-2549 (2013).
165. Xia, Y., Jeffrey Medeiros, L. & Young, K. H. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim. Biophys. Acta 1865, 58-71 (2016).
166. Care, M. A., Westhead, D. R. & Tooze, R. M. Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Med. 7, 96 (2015).